Ronald D Perrone

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. doi request reprint Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration
    Ronald D Perrone
    Tufts Medical Center, Boston, MA Electronic address
    Am J Kidney Dis 62:1046-57. 2013
  2. pmc Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease
    Ronald D Perrone
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin J Am Soc Nephrol 6:2508-15. 2011
  3. ncbi request reprint Left ventricular hypertrophy in ADPKD: changing demographics
    Ahsan Alam
    McGill University, Royal Victoria Hospital McGill University Health Centre, 687Pine Avenue West, Montreal, Canada H3A 1A1
    Curr Hypertens Rev 9:27-31. 2013
  4. pmc Tolvaptan in patients with autosomal dominant polycystic kidney disease
    Vicente E Torres
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 367:2407-18. 2012
  5. ncbi request reprint Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study
    Dana C Miskulin
    Tufts Medical Center, Boston, MA Electronic address
    Am J Kidney Dis 63:214-26. 2014
  6. pmc Analysis of baseline parameters in the HALT polycystic kidney disease trials
    Vicente E Torres
    Mayo Clinic College of Medicine, Rochester, Minnesota 55901, USA
    Kidney Int 81:577-85. 2012
  7. pmc Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study
    Vicente E Torres
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 57:692-9. 2011

Collaborators

Detail Information

Publications7

  1. doi request reprint Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration
    Ronald D Perrone
    Tufts Medical Center, Boston, MA Electronic address
    Am J Kidney Dis 62:1046-57. 2013
    ..Conference attendees addressed how PRO measures could be used to evaluate, monitor, provide care, and facilitate the introduction of treatments for patients with these challenging conditions...
  2. pmc Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease
    Ronald D Perrone
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin J Am Soc Nephrol 6:2508-15. 2011
    ..The HALT PKD study was designed to assess the effect of intensive angiotensin blockade on progression of total kidney volume and LVM. Measurements of LVM were performed using cardiac magnetic resonance (MR)...
  3. ncbi request reprint Left ventricular hypertrophy in ADPKD: changing demographics
    Ahsan Alam
    McGill University, Royal Victoria Hospital McGill University Health Centre, 687Pine Avenue West, Montreal, Canada H3A 1A1
    Curr Hypertens Rev 9:27-31. 2013
    ..The results of ongoing studies will help elucidate these relationships. ..
  4. pmc Tolvaptan in patients with autosomal dominant polycystic kidney disease
    Vicente E Torres
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 367:2407-18. 2012
    ..Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function...
  5. ncbi request reprint Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study
    Dana C Miskulin
    Tufts Medical Center, Boston, MA Electronic address
    Am J Kidney Dis 63:214-26. 2014
    ..We hypothesized that increased TKV would be a source of morbidity and diminished quality of life that would be worse in patients with more advanced disease...
  6. pmc Analysis of baseline parameters in the HALT polycystic kidney disease trials
    Vicente E Torres
    Mayo Clinic College of Medicine, Rochester, Minnesota 55901, USA
    Kidney Int 81:577-85. 2012
    ....
  7. pmc Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study
    Vicente E Torres
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 57:692-9. 2011
    ..We report baseline characteristics and revised power calculations for the trial...